Autoimmune-mediated vasculopathy.

Area of Science:

• Immunology
• Transplantation Biology
• Vascular Medicine

Background:

• Cyclosporine A (CsA) is an immunosuppressant used in organ transplantation.
• CsA use is linked to vasculopathy, a complication of chronic rejection.
• CsA can promote autoimmune responses by altering T cell populations.

Purpose of the Study:

• To investigate if CsA-induced autoreactive T cells cause vascular lesions in syngeneic heart grafts.
• To understand the mechanisms underlying CsA-associated graft vasculopathy.

Main Methods:

• Induction of autoimmunity with CsA or adoptive transfer of CsA-induced T cells in syngeneic heart graft models.
• Analysis of vascular changes, inflammatory infiltrates, and cytokine profiles.
• Evaluation of MHC class II-invariant chain peptide complex as a target antigen.
• Intervention with chloroquine to inhibit MHC class II upregulation.

Main Results:

• Graft vasculopathy developed in CsA-treated or T cell-transferred recipients.
• Vascular lesions showed medial inflammation, perivascular lymphocytic infiltration, and endothelial cell proliferation.
• Disease progression correlated with a shift from Type 1 to Type 2 cytokines.
• Upregulation of MHC class II-invariant chain peptide on endothelial cells was crucial for T cell targeting.
• Chloroquine treatment inhibited MHC class II upregulation and halted disease progression.

Conclusions:

• CsA-induced autoreactive T cells can mediate graft vasculopathy.
• The MHC class II-invariant chain peptide complex is a key target antigen in this process.
• Inhibiting MHC class II upregulation presents a potential therapeutic strategy against CsA-induced vasculopathy.